Dry Eye Syndrome Treatment Market, By Product Type, By Distribution Channel, By Geography

Description

Dry Eye Syndrome Treatment Market is estimated to be valued at USD 13,290 Mn in 2026 and is expected to reach USD 38,420 Mn by 2033, growing at a compound annual growth rate (CAGR) of 16.4% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 13,290 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	16.40%	2033 Value Projection:	USD 38,420 Mn

Dry eye syndrome (DES) is also known as keratisis sicca and keratoconjunctivitis sicca. Dry eye disease is a common condition that occurs when your tears aren't able to provide adequate lubrication for your eyes. Patients suffering from DES show damage to the ocular surface, instability in the tear film, and visual disturbance. Tear film covers the ocular surface which is made up of three intertwined layers, a superficial lipid layer produced by meibomian glands assist in reducing tear evaporation and uniform tear spreading, middle thick aqueous layer produced from lacrimal glands, and the innermost hydrophilic mucin layer produced from goblet cells of conjunctiva and epithelium of ocular surface. Dry eye syndrome is associated with a long list of causes which can be divided into primary and secondary. Dry eye may develop secondary to inflammatory disease (e.g. vascular, allergic), environmental conditions (e.g. allergens, cigarette smoke, dry climate), hormonal imbalance (e.g. perimenopausal women and patients under hormone replacement therapy), and contact lens wear. Other causes of dry eye are certain diseases, such as rheumatoid arthritis, Sjogren's syndrome, thyroid disease, and lupus Blepharitis (when eyelids are swollen or red), Entropion (when eyelids turn in), ectropion (eyelids turn outward) and being in smoke, wind or a very dry climate.

Market Dynamics

New dry eye therapies are introduced in the market with several new medications in the pipeline seeking approval. Strong product pipeline offers great market growth opportunity as approval of numerous pipeline products is expected to drive the market growth during the forecast period. For instance, in October 2021, Oyster Point Pharma, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of therapies to address ophthalmic disease, announce the U.S. Food and Drug Administration (FDA) approval for TYRVAYA (varenicline solution) Nasal Spray 0.03 mg, for the treatment of the signs and symptoms of dry eye disease. YRVAYA Nasal Spray is a selective cholinergic agonist delivered twice daily as an aqueous nasal spray into each nostril to activate basal tear production.

Key features of the study:

This report provides in-depth analysis of the global dry eye syndrome treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global dry eye syndrome treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include AbbVie Inc., Novartis AG, Bausch Health Companies Inc., Johnson & Johnson, Inc., I-MED Pharma inc., Santen Pharmaceutical Co., Ltd, AFT Pharmaceuticals, Novaliq GmbH, Otsuka Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries, Inc., Teva Pharmaceutical Industries Ltd., Mitotech, SA, Viatris Inc., among other prominent players
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global dry eye syndrome treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dry eye syndrome treatment market

Market Segmentation

Product Type Insights (Revenue, USD Mn, 2026 - 2033)
- Cyclosporine
- Oral Corticosteroid
- Artificial Tears
- Omega Supplements
- Punctual Bags
- Other
Distribution Channel Insights (Revenue, USD Mn, 2026 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Supermarket/ Hypermarket
- Online Pharmacies
Regional Insights (Revenue, USD Mn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- AbbVie Inc.
- Novartis AG
- Bausch Health Companies Inc.
- Johnson & Johnson, Inc.
- I-MED Pharma inc.
- Santen Pharmaceutical Co., Ltd
- AFT Pharmaceuticals
- Novaliq GmbH
- Otsuka Pharmaceutical Co., Ltd.
- Sun Pharmaceutical Industries, Inc.
- Teva Pharmaceutical Industries Ltd.
- Mitotech, SA
- Viatris Inc.

Product Code: CMI1173

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Recent Developments
Acquisitions and Partnerships Scenario
Technology Overview
Regulatory Scenario
PEST Analysis
Porter's Analysis

4. Global Dry Eye Syndrome Treatment Market, By Product Type, 2026-2033, (USD Mn)

Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Cyclosporine
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Oral Corticosteroid
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Artificial Tears
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Omega Supplements
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Punctual Bags
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Others
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

5. Global Dry Eye Syndrome Treatment Market, By Distribution Channel, 2026-2033, (USD Mn)

Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Hospital Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Retail Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Supermarket/ Hypermarket
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Online Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

6. Global Dry Eye Syndrome Treatment Market, By Region, 2026-2033, (USD Mn)

Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
North America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - U.S.
  - Canada
Latin America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - North Africa
  - Central Africa
  - South Africa

7. Competitive Landscape

AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Bausch Health Companies Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Johnson & Johnson, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
I-MED Pharma inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Santen Pharmaceutical Co., Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
AFT Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Novaliq GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Otsuka Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sun Pharmaceutical Industries, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Mitotech, SA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies